Management of TR3 Thyroid Nodules
For your 2.7 × 2 cm TR3 (mildly suspicious) nodule, fine-needle aspiration (FNA) is indicated because it meets the ACR TI-RADS size threshold of ≥2.5 cm, while the additional ≤10 mm nodule requires ultrasound follow-up at 1 year if it is also TR3. 1
Primary Nodule Management (2.7 × 2 cm TR3)
Why FNA is Recommended
The ACR TI-RADS establishes clear size-based thresholds that balance cancer detection against overdiagnosis of indolent disease. TR3 nodules carry approximately 5% malignancy risk and warrant FNA when they reach ≥2.5 cm 1. Your 2.7 cm nodule exceeds this threshold.
The rationale for this higher size cutoff (compared to other guidelines) is important:
- Ultrasound measurements tend to overestimate actual tumor size by approximately 0.7 cm on average 1
- SEER data analysis showed slight increases in distant metastases at 2.5 cm and mortality increases at 3 cm 1
- The goal is identifying clinically significant cancers while avoiding unnecessary biopsies of benign or indolent lesions
Key Point About Mixed Cystic-Solid Composition
Since your nodule is described as "mixed cystic and solid," the ACR TI-RADS instructs you to assign points based on the predominant solid component when calculating the TR score 1. This means the solid portion's characteristics (echogenicity, margins, shape, echogenic foci) determine the risk stratification, not the cystic component.
Secondary Nodule Management (≤10 mm)
If This Nodule is Also TR3:
- No FNA is indicated (too small at <2.5 cm threshold)
- Ultrasound follow-up at 1 year is recommended for TR3 nodules ≥1 cm 1
- If <1 cm, no follow-up is required per ACR TI-RADS
If This Nodule Has Different Characteristics:
- TR1-TR2: No FNA or follow-up needed
- TR4: Follow-up at 1 year (FNA threshold is 1.5 cm)
- TR5: FNA is indicated at ≥1 cm 1
Post-FNA Management Algorithm
If Bethesda II (Benign):
- No repeat FNA needed unless nodule characteristics change on ultrasound 2
- Size increase alone (without suspicious features) does not mandate repeat biopsy
- Continue surveillance imaging
If Bethesda III (Atypia/FLUS):
- Repeat FNA is advised 2
- If second FNA is again Bethesda III: surgery is usually recommended
- Active surveillance is an alternative for nodules ≤2 cm depending on patient factors 2
If Bethesda IV-VI:
- Surgery is generally recommended
- No need for repeat FNA 2
Important Caveats
Common Pitfall: Do not confuse "spongiform" with "mixed cystic-solid." Spongiform nodules must be >50% composed of small cystic spaces and are almost universally benign, requiring no points in TI-RADS scoring 1. A few scattered cystic components in a predominantly solid nodule does not qualify as spongiform.
Clinical Context Matters: While ACR TI-RADS provides size thresholds, consider:
- Patient age and comorbidities
- Compressive symptoms
- Patient anxiety and preference
- Growth on serial imaging
Limitations of Conservative Approach: Research shows that using ACR TI-RADS criteria, approximately 4.7% of malignant nodules ≥1 cm would not receive FNA recommendations 3. However, most of these would still undergo ultrasound follow-up, allowing detection of concerning changes over time.
Alternative Considerations
If the patient is not a surgical candidate or declines FNA, ultrasound-guided radiofrequency ablation has shown efficacy for mixed cystic-solid nodules with volume reduction rates of 67-75% at 1 year, though this is primarily studied for confirmed benign nodules 4, 5. This would not be appropriate without tissue diagnosis first.